| Literature DB >> 36042604 |
Liyan Wang1,2, Lin Wang3, Xia Yang1,2, Panpan Jin1,2, Rui Zhang1,2, Yanbiao Jiang4, Xuehong Zhang1,2.
Abstract
Early pregnancy loss (EPL) is a common complication of assisted reproductive technology treatment; however, the exact factors involved in EPL are not fully understood. This study aimed to evaluate the risk factors for EPL in fresh in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles. This retrospective cohort study was conducted on all couples who underwent clinical pregnancy in fresh IVF/ICSI cycles from January to December 2019 at a single large reproductive medical center. In total, 954 cycles were included in this study. Univariate and multivariate logistic regression analyses were performed to evaluate relevant risk factors for EPL. Curve fitting and threshold analyses were used to explore the association between risk factors and EPL. Compared with women with a normal total antral follicle count (AFC) (≥10, <15), those with a low AFC (<10) had a higher risk of EPL (odds ratio 2.97, 95% confidence interval: 1.38-6.38, P < .05). Patients with an estradiol/progesterone ratio (E2/P) ≥ 1.1 had significantly lower odds of EPL than women with E2/P < 1.1 (odds ratio 0.51, 95% confidence interval 0.28-0.91, P < .05). E2/P and serum human chorionic gonadotropin (hCG) levels negatively correlated with EPL. By using a 2-piecewise regression model, the inflection point of serum hCG level was 599.9 IU/L. Our results showed that lower AFC, E2/P, and serum hCG levels were associated with a higher EPL risk in fresh IVF/ICSI cycles.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36042604 PMCID: PMC9410683 DOI: 10.1097/MD.0000000000030166
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Basal characteristics of clinical pregnancies conceived in fresh IVF/ICSI cycles.
| Ongoing pregnancy | Early pregnancy loss |
| |
|---|---|---|---|
| N | 822 | 132 | |
| Maternal age (y) | <.001 | ||
| <35 | 641 (77.98%) | 87 (65.91%) | |
| ≥35, <40 | 147 (17.88%) | 25 (18.94%) | |
| ≥40 | 34 (4.14%) | 20 (15.15%) | |
| Maternal BMI (kg/m2) | .988 | ||
| <18.5 | 73 (9.06%) | 12 (9.45%) | |
| ≥18.5, <24 | 544 (67.49%) | 85 (66.93%) | |
| ≥24 | 189 (23.45%) | 30 (23.62%) | |
| Paternal age (y) | .002 | ||
| <35 | 585 (71.25%) | 77 (58.33%) | |
| ≥35, <40 | 162 (19.73%) | 31 (23.48%) | |
| ≥40 | 74 (9.01%) | 24 (18.18%) | |
| Type of infertility | .004 | ||
| Primary | 478 (58.15%) | 59 (44.70%) | |
| Secondary | 344 (41.85%) | 73 (55.30%) | |
| Duration of infertility (y) | 4.15 ± 4.73 | 4.17 ± 3.11 | .964 |
| Basal FSH (IU/L) | 6.70 ± 2.20 | 6.21 ± 2.04 | .067 |
| Basal LH (IU/L) | 5.66 ± 3.46 | 5.00 ± 2.54 | .110 |
| Basal E2 (pmol/mL) | 43.52 ± 28.98 | 48.58 ± 37.48 | .174 |
| Basal PRL (μg/L) | 19.26 ± 10.02 | 17.76 ± 8.22 | .220 |
| Basal TSH (IU/L) | 4.35 ± 8.95 | 4.33 ± 6.56 | .982 |
| CA-125 (U/mL) | 20.68 ± 16.26 | 20.28 ± 12.85 | .841 |
| Total AFC | .002 | ||
| <5 | 188 (23.30%) | 49 (37.69%) | |
| ≥10, <15 | 274 (33.95%) | 32 (24.62%) | |
| ≥15 | 345 (42.75%) | 49 (37.69%) |
Values are mean ± standard deviation or number (percentage).
AFC = total antral follicle count, BMI = body mass index, CA-125 = carbohydrate antigen 125, E2 = estradiol, FSH = follicle-stimulating hormone, IVF/ICSI = in vitro fertilization/intracytoplasmic sperm injection, LH = luteinizing hormone, PRL = prolactin, TSH = thyroid-stimulating hormone.
Treatment information of clinical pregnancies conceived in fresh IVF/ICSI cycles.
| Ongoing pregnancy | Early pregnancy loss |
| |
|---|---|---|---|
| N | 822 | 132 | |
| COH protocol | .278 | ||
| GnRH-a prolonged protocol | 303 (36.86%) | 44 (33.33%) | |
| GnRH-a short protocol | 1 (0.12%) | 1 (0.76%) | |
| GnRH-a long protocol | 459 (55.84%) | 72 (54.55%) | |
| GnRH antagonist protocol | 42 (5.11%) | 10 (7.58%) | |
| Minimal stimulation protocol | 15 (1.82%) | 5 (3.79%) | |
| Other protocol | 2 (0.24%) | 0 (0.00%) | |
| Gn stimulation days | 13.07 ± 1.91 | 12.61 ± 2.04 | .114 |
| Total Gn dose(IU) | 3114.43 ± 1325.50 | 3382.94 ± 1464.77 | .037 |
| Total Gn dose(IU) | .014 | ||
| <3150.73 | 508 (63.03%) | 65 (51.59%) | |
| ≥3150.73 | 298 (36.97%) | 61 (48.41%) | |
| E2/P | 2.48 ± 1.09 | 2.21 ± 1.08 | .009 |
| Number of retrieved oocytes | .176 | ||
| <6 | 70 (8.52%) | 13 (9.85%) | |
| ≥6, <15 | 401 (48.78%) | 74 (56.06%) | |
| ≥15 | 351 (42.70%) | 45 (34.09%) | |
| Number of metaphase-2 oocytes | .024 | ||
| <7 | 144 (17.52%) | 34 (25.76%) | |
| ≥7 | 678 (82.48%) | 98 (74.24%) | |
| Endometrial thickness(cm) | .201 | ||
| <0.8 | 13 (1.59%) | 5 (3.79%) | |
| ≥0.8, <1.2 | 451 (55.00%) | 68 (51.52%) | |
| ≥1.2 | 356 (43.41%) | 59 (44.70%) | |
| Fertilization methods | 0.211 | ||
| IVF | 550 (66.91%) | 81 (61.36%) | |
| ICSI | 272 (33.09%) | 51 (38.64%) | |
| Number of transferred embryos | .195 | ||
| 1 | 55 (6.69%) | 11 (8.33%) | |
| 2 | 707 (86.01%) | 106 (80.30%) | |
| 3 | 60 (7.30%) | 15 (11.36%) | |
| Serum hCG level(IU/L) | 1011.51 ± 789.25 | 495.19 ± 569.02 | <.001 |
Values are mean ± standard deviation or number (percentage).
COH = controlled ovarian hyperstimulation, Gn = gonadotropin, hCG = human chorionic gonadotropin, IVF/ICSI = in vitro fertilization/intracytoplasmic sperm injection.
Risk of early pregnancy loss by univariate and multivariate logistic regression analyses.
|
|
|
| ||
|---|---|---|---|---|
|
|
| |||
| Maternal age (y) | ||||
| <35 | Reference | Reference | ||
| ≥35, <40 | 1.25 (0.78, 2.02) | .3565 | 0.80 (0.40, 1.58) | .5215 |
| ≥40 | 4.33 (2.39, 7.87) | <.001 | 2.33 (0.90, 6.04) | .0816 |
| Paternal age (y) | ||||
| <35 | Reference | Reference | ||
| ≥35, <40 | 1.45 (0.93, 2.28) | .1045 | 1.32 (0.74, 2.34) | .3503 |
| ≥40 | 2.46 (1.47, 4.14) | <.001 | 1.33 (0.57, 3.09) | .5057 |
| Type of infertility | ||||
| Primary | Reference | Reference | ||
| Secondary | 1.72 (1.19, 2.49) | .0041 | 1.44 (0.91, 2.28) | .1158 |
| Total AFC | ||||
| <10 | 2.23 (1.38, 3.62) | .0011 | 2.97 (1.38, 6.38) | .0054 |
| ≥10, <15 | Reference | |||
| ≥15 | 1.22 (0.76, 1.95) | .4173 | 1.10 (0.64, 1.92) | .7242 |
| Total Gn dose (IU) | ||||
| <3150.73 | Reference | Reference | ||
| ≥3150.73 | 1.60 (1.10, 2.33) | .0147 | 1.34 (0.67, 2.69) | .4062 |
| E2/P | ||||
| <1.1 | Reference | Reference | ||
| ≥1.1 | 0.45 (0.26, 0.78) | .0043 | 0.51 (0.28, 0.91) | .0225 |
| Number of metaphase-2 oocytes | ||||
| <7 | Reference | Reference | ||
| ≥7 | 0.61 (0.40, 0.94) | .0252 | 0.82 (0.45, 1.48) | .5016 |
| Serum hCG level (IU/L) | ||||
| <591.7 | Reference | Reference | ||
| ≥591.7 | 0.19 (0.12, 0.28) | <.001 | 0.44 (0.21, 0.92) | .0304 |
AFC = total antral follicle count, CI = confidence interval, COH = controlled ovarian hyperstimulation, Gn = gonadotropin, hCG = human chorionic gonadotropin, IVF/ICSI = in vitro fertilization/intracytoplasmic sperm injection, OR = odds ratio.
Figure 1.(A) Multivariate-adjusted smoothing spline plots of early pregnancy loss rate by the total AFC. (B) Multivariate-adjusted smoothing spline plots of early pregnancy loss rate by E2/P. (C) Multivariate-adjusted smoothing spline plots of pregnancy loss rate by the serum hCG level. The red lines represent the smooth curve fits between variables. Analyses were adjusted for maternal age, paternal age, infertility type, total Gn dose, and number of metaphase-2 oocytes. AFC = antral follicle count, E2/P = estradiol/progesterone ratio, hCG = human chorionic gonadotropin.
Threshold effect analysis of serum hCG level on EPL using piecewise linear regression.
|
|
| |
|---|---|---|
|
| ||
| Model I | ||
| One line slope | 0.9981 (0.9976, 0.9986) | <.001 |
| Model II | ||
| Inflection point (K) | 599.9 | |
| Slope 1: hCG < 599.9 IU/L | 0.9945 (0.9933, 0.9958) | <.001 |
| Slope 2: hCG ≥ 599.9 IU/L | 0.9998 (0.9993, 1.0003) | .429 |
| Slope 2-Slope 1 | 1.0053 (1.0037, 1.0069) | <.001 |
| A log likelihood ratio test | <.001 | |
Adjusted for maternal age, paternal age, type of infertility, total Gn dose, number of metaphase-2 oocytes.
CI = confidence interval, early pregnancy loss, EPL, hCG = human chorionic gonadotropin, OR = odds ratio.